Cardiology

Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea is Safe and Effective in Patients with Concomitant Cardiac Devices.


Related Articles

Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea is Safe and Effective in Patients with Concomitant Cardiac Devices.

Heart Rhythm. 2020 Jun 30;:

Authors: Nayak HM, Patel R, McKane S, James KJ, Meyer TE, Germany RE, Stellbrink C, Costanzo MR, Augostini R

Abstract
BACKGROUND: Central sleep apnea is common in heart failure patients. Transvenous phrenic nerve stimulation (TPNS) requires placing a lead to stimulate the phrenic nerve and activate the diaphragm. Data are lacking concerning the safety and efficacy of TPNS in patients with concomitant cardiovascular implantable electronic devices (CIEDs).
OBJECTIVE: The objective is to report the safety and efficacy of TPNS in patients with concomitant CIEDs.
METHODS: In the remedē System Pivotal Trial, 151 patients underwent TPNS device implant. This analysis compared patients with concomitant CIEDs to those without with respect to safety, implant metrics and efficacy of TPNS. Safety was assessed using incidence of adverse events and device-device interactions. A detailed interaction protocol was followed. Implant metrics included overall TPNS implantation success. Efficacy endpoints included changes in the apnea-hypopnea index (AHI) and quality of life.
RESULTS: Of 151 patients, 64 (42%) had a concomitant CIED. There were no significant differences between the groups with respect to safety. There were 4 CIED oversensing events in 3 patients leading to one inappropriate defibrillator shock and delivery of anti-tachycardia pacing. There was no difference in efficacy between the CIED and non-CIED subgroups receiving TPNS, with both having similar percentages of patients who achieved ≥ 50% reduction in AHI and quality of life improvement.
CONCLUSION: Concomitant CIED and TPNS therapy is safe. The presence of a concomitant CIED did not appear to impact implant metrics, implantation success and TPNS efficacy. A detailed interaction protocol should be followed to minimize the incidence of device-device interaction.

PMID: 32619739 [PubMed – as supplied by publisher]

Source link

Related posts

Knockdown of TUG 1 suppresses hypoxia-induced apoptosis of cardiomyocytes by up-regulating miR-133a.

Newsemia

Time in collars and collar-related complications in older patients.

Newsemia

Prevention of Heart Attack and Stroke-Early Detection Of Risk Using Coronary Artery Calcium Scans In The Youngish

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World